DermatologyNews.net

Dermatology Xagena

Psoriasis is a chronic inflammatory disease associated with increased risk of cardiovascular death. Several studies have shown a beneficial effect of anti-TNF-alpha therapy on the mechanisms associate ...


Results from additional efficacy and safety analyses of Apremilast ( Otezla ) from the ESTEEM phase III clinical trial program were presented at the 23rd European Academy of Dermatology and Venereolog ...


The Dermatologic and Ophthalmic Drugs Advisory Committee ( DODAC ) to the US Food and Drug Administration ( FDA ) has voted unanimously to support the approval of AIN457 ( Secukinumab ), a selective i ...


Results from a phase 2b dose-ranging study of Dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis, a serious, chronic form of eczema were presented. All ...


Results from a phase 3 pivotal study demonstrating that Adalimumab ( Humira ) is effective in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa ( HS ), specifi ...


Thiazolidinediones ( also known as glitazones ) have shown to be efficacious with a favorable safety profile when used in the treatment of chronic plaque-type psoriasis. The aim of a study was to ...


Sentinel-node biopsy, a minimally invasive procedure for regional melanoma staging, was evaluated in a phase 3 trial. Researchers have evaluated outcomes in 2001 patients with primary cutaneous melan ...


In the BRIM-3 trial, Vemurafenib ( Zelboraf ) was associated with risk reduction versus Dacarbazine ( Deticene ) of both death and progression in patients with advanced BRAFV600 mutation-positive mela ...


Results from two pivotal phase III studies evaluating the interleukin-17A ( IL-17A ) inhibitor Secukinumab ( AIN457 ) were published in the New England Journal of Medicine ( NEJM ). Secukinumab met ...


A meta-analysis has evaluated the efficacy and safety of Ustekinumab ( Stelara ) in the therapy of plaque psoriasis. The efficacy was estimated using relative risk of Psoriasis Area and Severity In ...


Certain acne treatments can, in rare instances, cause severe allergic reactions that are potentially life-threatening. The Food and Drug Administration ( FDA ) is warning that the use of certain acne ...


Bristol-Myers Squibb ( BMS ) has announced that a randomized blinded comparative phase 3 study evaluating Nivolumab versus Dacarbazine ( DTIC ) in patients with previously untreated BRAF wild-type adv ...


A man with almost no hair on his body has grown a full head of it after a novel treatment by clinicians at Yale University. There is currently no cure or long-term treatment for alopecia universalis, ...


Psoriasis is an inflammatory disorder, which has been reported to be associated with cardiovascular risks. Although increased cardiovascular risks in psoriasis are well established, there are no data ...


A post hoc analysis has examined the effects of Adalimumab ( Humira ) in patients with scalp and/or nail psoriasis from BELIEVE, a randomized, controlled, multicentre phase 3 safety and efficacy trial ...


New findings on Apremilast ( Otezla ), a selective inhibitor of phosphodiesterase 4 ( PDE4 ), from the ESTEEM 1 and 2 phase III studies in patients with moderate to severe plaque psoriasis were presen ...


Tofacitinib ( Xeljanz ) is a novel, oral Janus kinase inhibitor currently under investigation for plaque psoriasis. This exploratory analysis of a phase IIb, 12-week, dose-ranging study has evaluat ...


Vismodegib ( Erivedge ), a first-in-class Hedgehog pathway inhibitor, was Food and Drug Administration ( FDA ) approved for advanced basal cell carcinomas ( BCCs ) based on a single, nonrandomized, ph ...


OBSERVE-5 was a 5-year FDA-mandated surveillance registry of patients with psoriasis. Researchers have assessed long-term Etanercept ( Enbrel ) safety and effectiveness. Patients with moderate to s ...


Vismodegib ( Erivedge ), the first Food and Drug Administration ( FDA )-approved Hedgehog ( Hh ) signaling pathway inhibitor, in the treatment of advanced basal cell carcinoma ( BCC ). Activation o ...



2000-2014© XAGENA srl - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati